COMPARATIVE STUDY TO EVALUATE EFFICACY OF METFORMIN VERSUS SITAGLIPTIN ALONE AND IN COMBINATION IN TYPE 2 DIABETES MELLITUS

Main Article Content

Dibyadeb Ghosh
Irfan Ahmad Khan
Rahul Kr Shukla

Keywords

Type 2 diabetes mellitus, DPP-4 inhibitors, novel therapeutic approach, HbA1c

Abstract

Background: Type 2 diabetes mellitus is characterized by high blood glucose, insulin resistance, and a relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss. Metformin, a biguanide agent, acts primarily as an insulin sensitizer. Its primary clinical site of action is in the liver, improving hepatic insulin sensitivity and, as a result, decreasing hepatic gluconeogenesis. Sitagliptin is an oral, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of patients with Type 2 Diabetes Mellitus. 


Materials and methods:It was a Prospective, Comparative, open-label, multiple follow-up study, including 270 patients. All the patients were randomly divided into three groups: Group I (90 patients; received Metformin 500 mg BD) and Group II (90 patients received sitagliptin 50 mg BD), Whereas Group III (90 subjects received Metformin 500 mg BD along with Sitagliptin 50 mg BD for 3 months)


Result: The mean fasting blood glucose level in Group I at baseline was 145.18±7.44 mg/dl and after 3 months was reduced to 95.89±6.55 mg/dl, in Group II it was 147.29±7.52 mg/dl, and after 3 months reduced to 89.52±6.25 mg/dl. The mean PPG level in Group I was 196.28±16.63 mg/dl at baseline, followed by 154.73±11.29 mg/dl after the 3rd month. However, In Group II, the mean PPG level was 199.84±16.58 mg/dl at baseline, reduced by 133.52±10.69 mg/dl after the 3rd month. In Group III, the mean PPG level was 198.68±15.69 mg/dl at baseline, followed by 129.79±11.42 mg/dl after the 3rd month


Conclusion: From the findings- both groups showed significant improvement in FPG, PPG, and HbA1. However glycaemic control was highly improved in combination with Metformin and Sitagliptin

Abstract 433 | Pdf Downloads 205

References

1. Reasner, C., Olansky, L., Seck, T. L., WilliamsHerman, D. E., Chen, M., Terranella, L., & Goldstein, B. J. (2011). The effect of initial therapy with the fixed‐ dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 13(7), 644-652.
2. Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., & Williams-Herman, D. E. (2007). Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes care, 30(8), 1979-1987.
3. Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011). Secretion of glucagonlike peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?.Diabetologia, 54(1), 10-18.
4. Langley, A. K., Suffoletta, T. J., & Jennings, H. R. (2007). Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 27(8), 1163-1180.
5. Brazg, R., Xu, L., Dalla Man, C., Cobelli, C., Thomas, K., & Stein, P. P. (2007). Effect of adding sitagliptin, a dipeptidyl peptidase‐ 4 inhibitor, to metformin on 24‐ h glycaemic control and β‐ cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 9(2), 186-193.
6. Williams‐ Herman, D., Johnson, J., Teng, R., Golm, G., Kaufman, K. D., Goldstein, B. J., &Amatruda, J. M. (2010). Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 12(5), 442-451.
7. Reasner, C., Olansky, L., Seck, T. L., WilliamsHerman, D. E., Chen, M., Terranella, L., ... & Goldstein, B. J. (2011). The effect of initial therapy with the fixed‐ dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 13(7), 644-652.
8. Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., & Williams-Herman, D. E. (2007). Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes care, 30(8), 1979-1987.
9. Ferreira AJC, Amatruda JM. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type-2 diabetes: a randomized, double-blind trial. Diabetes ObesMetab. 2010;12:613-22.
10. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Herman WDE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-87.
11. Jacques N. New NICE guidelines for type II diabetes treatment. clinical update: Br J Clinic Pharm. 2009;1:167-8.
12. Kurebayashi S, Motomura T, Goya K, Nakao M, Hashimoto K. Sitagliptin significantly decreases the ratio of glycated albumin to HbA1c in patients with type 2 diabetes mellitus. J Diabetes Metab. 2014;5:343.
13. Reasner, C., Olansky, L., Seck, T. L., WilliamsHerman, D. E., Chen, M., Terranella, L., ... & Goldstein, B. J. (2011). The effect of initial therapy with the fixed‐ dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 13(7), 644-652.
14. Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., & Williams-Herman, D. E. (2007). Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes care, 30(8), 1979-1987.
15. Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011). Secretion of glucagonlike peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?.Diabetologia, 54(1), 10-18.
16. Langley, A. K., Suffoletta, T. J., & Jennings, H. R. (2007). Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 27(8), 1163-1180.
17. Brazg, R., Xu, L., Dalla Man, C., Cobelli, C., Thomas, K., & Stein, P. P. (2007). Effect of adding sitagliptin, a dipeptidyl peptidase‐ 4 inhibitor, to metformin on 24‐ h glycaemic control and β‐ cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 9(2), 186-193.
18. Williams‐ Herman, D., Johnson, J., Teng, R., Golm, G., Kaufman, K. D., Goldstein, B. J., &Amatruda, J. M. (2010). Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 12(5), 442-451.